Stemline Therapeutics, Inc. (STML)

Oncology Corporate Profile

Stock Performance

10.2000
0.0000

HQ Location

750 Lexington Avenue, 11th Floor
New York, NY 10022

Company Description

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel oncology therapeutics that target both cancer stem cells (CSCs) and tumor bulk in a variety of cancer types. Stemline is currently developing two clinical-stage product candidates, SL-401 and SL-701.

Website: http://www.stemline.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
SL-401interleukin-3 receptor (IL-3R)Acute Myelogenous Leukemia (AML)II
SL-701 (+ immunostimulant and bevacizumab)immunotherapyGlioblastoma Multiforme (GBM)I
SL-801XPO1 inhibitorVarious cancer typesI

Source: http://www.stemline.com

Recent News Headlines

7/24/2017 06:20 pm

7/24/2017 06:20 pm

7/24/2017 06:20 pm

7/24/2017 06:20 pm

6/29/2017 06:19 pm

6/29/2017 06:19 am

6/29/2017 06:19 am

6/23/2017 06:19 am

6/23/2017 06:19 am

6/23/2017 06:19 am

6/23/2017 06:19 am

6/6/2017 06:19 am

6/6/2017 06:19 am

6/6/2017 06:19 am

6/6/2017 06:19 am

5/31/2017 06:19 am

5/31/2017 06:19 am

5/31/2017 06:19 am

5/31/2017 06:19 am

5/31/2017 06:19 am

5/18/2017 06:19 am

5/16/2017 06:19 am

5/10/2017 12:19 pm

5/2/2017 06:19 pm

5/1/2017 12:19 am